市场调查报告书
商品编码
1447725
大麻二酚市场评估:按物种、给药途径、形式、治疗用途、最终用户和地区划分的机会和预测(2017-2031)Cannabidiol Market Assessment, By Species, By Route of Administration, By Form, By Therapeutic Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
全球大麻二酚市场规模预计将从2023年的80.4亿美元成长到2031年的302.2亿美元,2024-2031年预测期间复合年增长率为18%,预计规模还将不断扩大。
全球大麻二酚市场的发展受到多种因素的推动,包括 CBD 在医疗保健行业的药用用途的扩大以及领先公司增加研发以研究 CBD 在各种医疗条件下的潜在益处。 人们对安全使用 CBD 治疗癫痫等健康状况的接受度不断提高,这也导致了全球市场的成长。 各国CBD的合法化正在增加公共和私人机构投资大麻二酚市场的兴趣。 主要参与者、新创公司和合资企业的存在,以及这些公司的併购、联盟、分销协议和频繁的新产品发布,正在推动全球大麻二酚市场的成长。
由于 CBD 作为治疗焦虑、忧郁、慢性疼痛、癫痫等药物的广泛应用,全球大麻二酚市场正在经历显着增长。 CBD因其巨大的治疗功效潜力而被广泛应用于製药业,如CBD油、胶囊和外用乳膏。 因此,一些公共和私人组织正在增加对研发活动的投资,以进一步发现 CBD 的治疗益处。 近年来,患者和医疗保健提供者越来越接受 CBD 用于医疗目的,导致 CBD 市场的需求增加。
有利的监管架构在加强全球 CBD 市场方面也发挥着重要作用。 将 CBD 用于医疗目的在各国正在变得合法。 此外,公司之间频繁的併购和合作协议等合作活动、主要参与者不断推出创新产品以及新进业者也进一步推动了全球大麻二酚市场的发展。
心理健康问题增加
随着世界人口中焦虑和忧郁等精神疾病的数量不断增加,对大麻二酚的需求激增。 世界卫生组织(WHO)指出,忧郁症等精神疾病已成为当今生活中常见的健康状况。 全球约有3.8%的人口患有忧郁症,其中5%的成年人和5.7%的60岁以上人口患有忧郁症。
有利的监理架构
随着对基于 CBD 的产品的需求不断增长,FDA 等监管机构正在考虑改进并引入新的监管途径,以支持 CBD 产品在医学中的道德和安全使用。事实确实如此。 2023年1月,美国FDA宣布将重新评估含有大麻二酚产品的监管架构。
本报告调查了全球大麻二酚市场,提供了市场定义和概述、市场规模趋势和预测、各个细分市场和地区的详细分析、行业结构以及影响市场成长的因素分析、案例研究、竞争格局、简介关键公司等。
Global cannabidiol market is projected to witness a CAGR of 18% during the forecast period 2024-2031, growing from USD 8.04 billion in 2023 to USD 30.22 billion in 2031. The market has experienced significant growth in recent years and is expected to maintain a strong pace of expansion in the coming years.
Growth in the global cannabidiol market is being driven by various factors such as increased medicinal application of CBD in the healthcare industry and increased research and development by leading players to study the potential benefits of CBD in different medical conditions. Growing acceptance among people regarding the safe usage of CBD for health conditions such as epilepsy is leading to the growth of this market globally. Increased legalization of CBD across different countries is enhancing the interest of public and private organizations in investing in the cannabidiol market. The presence of several top players, new companies, and collaborative ventures such as mergers and acquisitions, partnerships, distribution agreements, and frequent new product launches are driving the growth of the global cannabidiol market.
The global cannabidiol market is undergoing significant growth due to the increasing application of CBD for medicinal purposes such as anxiety, depression, chronic pain, and epilepsy. CBD is widely used by the pharmaceutical industry as CBD oils, capsules, and topical creams, due to its huge potential in providing therapeutical advantages. As a result, several public and private organizations are increasingly investing in research and development activities to find out more therapeutical benefits of CBD. Over the years, there has been an increased acceptance of CBD usage for medicinal purposes among patients and healthcare providers, leading to a growing demand for the CBD market.
A favorable regulatory framework plays a crucial role in enhancing the global CBD market. There has been increased legalization of the usage of CBD for medicinal purposes across different countries. The act is enhancing and expanding the CBD market at a global level. Moreover, frequent collaboration activities such as mergers and acquisitions, partnership agreements between the companies, consistent innovative product launches by the key market players, along with new entrances, further propels the global cannabidiol market. In December 2023, Rare Cannabinoid Company announced the launch of THC + THCV Uplift Gummies. This product has been launched for the United States consumers to increase focus, energy, and control hunger.
Increasing Prevalence of Mental Health Problems
There has been a surge in demand for cannabidiol due to the rising number of mental illnesses such as anxiety and depression among the global population. Mental health conditions are not uncommon these days and affect a larger section of people from all over the world. The World Health Organization states that mental disorders such as depression have become a common health condition in today's life. Globally, around 3.8% of the population is affected by depression, includes 5% of adults and 5.7% of people aged 60 years and above.
WHO states that, globally, there are around 280 million people who suffer from depression. Depression is more common among women compared to men. Globally, 10% of pregnant and post-partum women experience depression every year. WHO states that every year more than 700,000 people die due to suicide. Several studies have shown the potential of CBD in managing depression and anxiety, which has substantially led to improvement in the health condition of the people. Hence, many organizations are incorporating CBD for developing CBD-based products.
Favorable Regulatory Framework
With the growing demand for CBD-based products, there has been consideration within the regulatory bodies such as FDA, to improve and bring new regulatory pathways to support the ethical and safe use of CBD-based products in the healthcare industry. In January 2023, the Food and Drug Administration in the United States announced that it is now re-evaluating the regulatory framework for goods containing cannabidiol. The FDA has determined that the current regulatory frameworks for foods and supplements do not apply to CBD and that a new regulatory approach is required to initiate a compromise between the requirement for consumer safety and people's desire to have access to CBD products. To create a new cross-agency approach to the regulation of these items, the FDA is ready to collaborate with Congress. This favorable change in the current regulatory systems is expected to accelerate the development of cannabidiol.
Consumption of CBD Oil is Witnessing Significant Demand
Among the form segments, CBD oil segment holds a significant market share in the global cannabidiol market. In comparison with other forms of cannabidiol, CBD oil has vast application areas such as in pain management, epilepsy, nutraceuticals and beauty. CBD oils are legal and easy to access, which makes it highly popular among manufacturers and consumers. Additionally, several leading players are launching CBD oils for various medical purposes in their product portfolio, which is enhancing the growth of the global cannabidiol market. For instance, in September 2023, Aurora Cannabis Inc., a Canada based medical cannabis company announced an expansion of its hemp-derived CBD portfolio in Brazil. The company is all set to launch full-spectrum, single-source 3% CBD oil, to cater to the need of the consumers in Brazil.
Application of CBD in Treating Epilepsy
Among the therapeutic application segment, CBD is widely used for the treatment of epilepsy and thus, the segment holds a significant market share in the overall global cannabidiol market. Cannabidiol has shown promising positive effects in the treatment of epilepsy, especially in certain epileptic syndromes such as Lennox-Gastaut syndrome and Dravet syndrome. Regulatory bodies such as the European Medicines Agency and the U.S. Food and Drug Administration have approved CBD for use in certain epilepsy treatments.
Moreover, key market players are bringing new product launches in this segment to improve the health conditions of the patients, which is further accelerating the growth of the segment. In January 2023, Medical Marijuana, Inc. subsidiary "HempMeds Brasil" successfully launched two new CBD-based products in Brazil to help in the treatment process of epilepsy. HempMeds Brasil is authorized to provide its CBD-based products, under medical prescription to aid in the management of diseases such as epilepsy, Parkinson's, chronic pain, and multiple sclerosis.
North America Dominates Global Cannabidiol Market
North America holds the largest share in global cannabidiol market, due to various factors such as the presence of major manufacturers including Medical Marijuana Inc. and Tilray Inc., increased acceptance among healthcare providers and people regarding using CBD-based products for medical conditions such as anxiety, depression, epilepsy, and pain management driving high demand for cannabidiol. Additionally, favorable laws regarding the usage of CBD products in most of the countries in North America are enhancing the growth of the market.
Medical Marijuana Inc., stated that in the United States, there are around 33 states, that have legalized safe usage of marijuana and there are more states that are expected to receive permission to legalize cannabinoid usage in the future. Consequently, along with the re-formation of federal law, it is expected that North America will further undergo tremendous growth in the cannabidiol market and will maintain its leadership in the forecast period as well.
Future Market Scenario (2024 - 2031F)
The global cannabidiol market is expected to grow in the future due to multiple factors. The increasing prevalence of anxiety and depression among the population has enhanced the company's focus in developing CBD-based products that can help with relieving mental stress among the users. Increased acceptance among healthcare providers regarding the capabilities of CBD in the treatment of anxiety, depression, and epilepsy has enabled pharmaceutical companies to increase investments in the market. There has been a surge in research and development activities in the market to further explore the potential benefits of CBD in patient treatments. Collaborative ventures among the companies, improved and supportive regulatory framework, and new entrants have spurred growth in the global cannabidiol market. According to an article published in the "Hartford Business Journal" many CBD companies are planning to start their operations in 2023 and 2024. Along with it, new retailers, manufacturers, and products are expected to enter the cannabidiol market, which will further assist in driving the market growth.
Key Players Landscape and Outlook
In cannabidiol market, several pharmaceutical companies are consistently establishing strategic partnerships, and distribution agreements, which play a pivotal role in driving the demand for cannabidiol products. These partnerships enable firms to gain informative insights regarding the market, take advantage of each other's resources, markets, and technologies, and invest in research and development activities to bring advancements in the market. Distribution agreements enable companies to broaden their market presence at a global level. These collaborative initiatives promote innovation, expertise product development and contribute to the enduring and robust growth of the global market.
For instance, in August 2023, Medical Marijuana, Inc., announced that Kannaway, which is its subsidiary, completed acquisition of a Japan based network marketing company "EXfuse, LLC, dba KZ1". The acquisition will expand the company's business in Japan and the KZ1's premium products such as nootropics-based products enhancing the company's CBD product portfolio. The partnership further aims to bring innovative product launches in their various business segments such as natural health, beauty, and CBD products.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.